Table 2.
The Clinical Status in Eight Consecutive Transthyretin Amyloid Cardiomyopathy Patients at the Time of Pimobendan Administration and Their Clinical Course (Present Case Is Patient 1).
| No | Diagnosis | Age | NYHA class | Clinical status | Pimobendan dose | EF (%) | BNP (pg/mL) | eGFR (mL/ min/1.73 m2) |
Clinical course |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATTRwt | 71 | 4 | In hospital and dobutamine dependent, 3 times HF hospitalization | 2.5 mg | 43 | 479.2 | 49.0 | Free hospitalization and alive for 4 months |
| 2 | ATTRwt | 78 | 3 | In hospital, 10 times HF hospitalization | 2.5 mg | 35 | 630.5 | 30.1 | 3 times HF hospoitalization and HF death after 8 months |
| 3 | ATTRwt | 76 | 3 | Outpatient clinic, 3 times HF hospitalization | 1.25 mg | 35 | 220.9 | 23.1 | 3 times HF hospoitalization and alive for 2 years |
| 4 | ATTRwt | 78 | 4 | In hospital, 3 times HF hospitalization | 1.25 mg | 50 | 1,450.8 | 23.6 | Discharged and HF death after 2 months |
| 5 | ATTRwt | 78 | 4 | In hospital, 3 times HF hospitalization | 2.5 mg | 34 | NA | NA | 2 times HF hospoitalization and HF death after 8 months |
| 6 | ATTRwt | 85 | 4 | In hospital and dobutamine dependent, 5 times HF hospitalization | 1.25 mg | 33 | NA | NA | Temporary going home for 1 day and HF death after 1 week |
| 7 | *ATTR | 84 | 3 | Outpatient clinic, 2 times HF hospitalization | 1.25 mg | 38 | NA | NA | Free hospitalization and alive for 4 months |
| 8 | ATTRv | 66 | 3 | Outpatient clinic, 3 times HF hospitalization | 1.25 mg | 32 | 573.2 | 25.2 | Free hospitalization and alive for 1 year |
*ATTR: no genetic testing.
ATTRwt: wild-type transthyretin amyloid cardiomyopathy, ATTRv: variant (familial) transthyretin amyloid cardiomyopathy, NYHA class: New York Heart Association class, HF: heart failure, EF: ejection fraction, BNP: brain natiriuretic peptide, eGFR: estimated glomerular filtration rate, NA: not available